Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped

Roche has a new GLP-1 weight loss drug in the works -- and one very cheap stock. A simpler dosage method Is Roche stock a buy? But good news for Roche is bad news for the companies that now seem to have the weight-loss drug market to themselves. Shares of Eli Lilly (LLY -2.62%) were down 2.8% today, and Novo Nordisk (NVO -3.51%) lost 4%. This isn't great news for Lilly and Novo Nordisk, both of which have blockbuster GLP-1 drugs on the market -- Zepbound and Mounjaro for Lilly, and Ozempic and Wegovy for No ...